Why the study?
To evaluate the feasibility of prolonged enoxaparin therapy as an alternative to standard-of-care unfractionated heparin with or without a glycoprotein IIb/IIIa antagonist in opiate-treated STEMI patients undergoing primary angioplasty.
Does a prolonged 6-hour enoxaparin regimen improve safety and feasibility compared to standard-of-care unfractionated heparin in opiate-treated STEMI patients undergoing primary PCI?
Does a prolonged 6-hour enoxaparin regimen improve safety and feasibility compared to standard-of-care unfractionated heparin in opiate-treated STEMI patients undergoing primary PCI?
A novel 6-hour enoxaparin regimen appears feasible and safe compared to standard unfractionated heparin with or without GPI in opiate-treated STEMI patients undergoing primary PCI.
Answers are grounded in this paper and cite their sources.
Supports 6-hour enoxaparin as feasible alternative in opiate-treated STEMI PCI; extends limited RCT data on periprocedural anticoagulation.
inhibitors in opiate-treated ST-elevation myocardial infarction (STEMI) patients undergoing primary angioplasty. We aimed to study the feasibility of this regimen as an alternative to standard-of-care treatment (SOC) with unfractionated heparin ± glycoprotein IIb/IIIa antagonist (GPI). One hundred opiate-treated patients presenting with STEMI and accepted for primary angioplasty were randomized (1:1) to either enoxaparin or SOC. Fifty patients were allocated enoxaparin (median age 61, 40% females) and 49 allocated SOC (median age 62, 22% females). One developed stroke before angiography and was withdrawn. One SOC patient had a gastrointestinal bleed resulting in 1 g drop in hemoglobin and early cessation of GPI infusion. Two enoxaparin patients had transient minor bleeding: one transient gingival bleed and one episode of coffee ground vomit with no hemoglobin drop or hemodynamic instability. Two SOC and no enoxaparin group patients had acute stent thrombosis. These preliminary data support further study of this novel 6-hour enoxaparin regimen in opiate-treated PPCI patients.
No takes yet. Share an insight, caveat, or question.
Sumaya et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: